Literature DB >> 24423336

Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial.

Solhild Stridsklev1, Sven M Carlsen, Øyvind Salvesen, Ilka Clemens, Eszter Vanky.   

Abstract

CONTEXT: Metformin is used to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS), although it is not approved for this indication and solid evidence is lacking. Midpregnancy Doppler ultrasound is one of the best methods for prediction of adverse pregnancy outcome.
OBJECTIVE: The objectives of the study were to investigate the following: 1) whether metformin treatment influenced the midpregnancy pulsatility index (PI) of the uterine artery; 2) whether metabolic or endocrine factors affect the PI of the uterine artery of PCOS women; and 3) whether PI predicted adverse pregnancy outcome in PCOS woman.
DESIGN: This is a substudy of a randomized, placebo-controlled, double-blind, multicenter study conducted at 11 secondary care centers. We randomly assigned 273 pregnancies to receive metformin or placebo, from the first trimester of pregnancy to delivery. In the present substudy, 231 pregnancies are included, ie, those who completed the ultrasound examinations. MAIN OUTCOME MEASURES: Midpregnancy PI in the uterine artery related to metformin use, androgen levels, an oral glucose tolerance test, and insulin levels was measured. We found no difference in the PI between the metformin and placebo groups. In multivariate analyses, fasting serum glucose of the first and second trimester correlated positively to the midpregnancy PI. Only in univariate analyses a weak correlation between androstenedione and PI was seen.
CONCLUSIONS: Metformin treatment did not affect uterine artery blood flow, measured by PI. High fasting blood glucose correlated inversely to uterine artery blood flow. The midpregnancy PI correlated positively to preeclampsia, hypertension, and gestational diabetes mellitus in PCOS pregnancies. Androgen levels correlated only to PI in univariate analyses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24423336     DOI: 10.1210/jc.2013-3227

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Metformin exposure, maternal PCOS status and fetal venous liver circulation: A randomized, placebo-controlled study.

Authors:  Sindre Grindheim; Cathrine Ebbing; Henriette Odland Karlsen; Svein Magne Skulstad; Francisco Gómez Real; Marianne Lønnebotn; Tone Løvvik; Eszter Vanky; Jørg Kessler
Journal:  PLoS One       Date:  2022-01-28       Impact factor: 3.240

2.  Observations of the Effects of Maternal Fasting Plasma Glucose Changes in Early Pregnancy on Fetal Growth Profiles and Birth Outcomes.

Authors:  Fei Guo; Yindi Liu; Zheng Ding; Yong Zhang; Chen Zhang; Jianxia Fan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-19       Impact factor: 5.555

Review 3.  The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus.

Authors:  Joselyn Rojas; Mervin Chávez-Castillo; Valmore Bermúdez
Journal:  Int J Reprod Med       Date:  2014-12-08

4.  Uterine Artery Doppler in Pregnancy: Women with PCOS Compared to Healthy Controls.

Authors:  Solhild Stridsklev; Øyvind Salvesen; Kjell Åsmund Salvesen; Sven M Carlsen; Eszter Vanky
Journal:  Int J Endocrinol       Date:  2018-08-16       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.